Standard

Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands. / van Deursen, Anna M. M.; van Mens, Suzan P.; Sanders, Elisabeth A. M. et al.

In: Emerging infectious diseases, Vol. 18, No. 11, 2012, p. 1729-1737.

Research output: Contribution to journalArticleAcademicpeer-review

Harvard

van Deursen, AMM, van Mens, SP, Sanders, EAM, Vlaminckx, BJM, de Melker, HE, Schouls, LM, de Greeff, SC & van der Ende, A 2012, 'Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands', Emerging infectious diseases, vol. 18, no. 11, pp. 1729-1737. https://doi.org/10.3201/eid1811.120329

APA

van Deursen, A. M. M., van Mens, S. P., Sanders, E. A. M., Vlaminckx, B. J. M., de Melker, H. E., Schouls, L. M., de Greeff, S. C., & van der Ende, A. (2012). Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands. Emerging infectious diseases, 18(11), 1729-1737. https://doi.org/10.3201/eid1811.120329

Vancouver

van Deursen AMM, van Mens SP, Sanders EAM, Vlaminckx BJM, de Melker HE, Schouls LM et al. Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands. Emerging infectious diseases. 2012;18(11):1729-1737. doi: 10.3201/eid1811.120329

Author

van Deursen, Anna M. M. ; van Mens, Suzan P. ; Sanders, Elisabeth A. M. et al. / Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands. In: Emerging infectious diseases. 2012 ; Vol. 18, No. 11. pp. 1729-1737.

BibTeX

@article{5c67493d167b42809eb26c7ff101b5ca,
title = "Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands",
abstract = "In the Netherlands, the national immunization program includes 7-valent pneumococcal conjugate vaccine (PCV7) for all newborns born after April 1, 2006. We compared the incidence of invasive pneumococcal disease (IPD) and patient and disease characteristics before PCV7 introduction (June 2004-June 2006) with those after PCV7 introduction (June 2008-June 2010). Culture-confirmed IPD cases were identified by 9 sentinel laboratories covering ≈25% of the Dutch population. Significant declines in overall IPD incidence were observed in children <2 (60%) and in persons >65 (13%) years of age. A trend toward gradual increases in non-PCV7 serotype IPD infections was observed in all age groups; the largest increases were among persons 50-64 (37%) and >65 (25%) years of age. In adults, the proportion of immunocompromised persons increased among IPD patients. Overall, deaths from IPD decreased from 16% to 12% because of a lower case-fatality rate for persons with non-PCV7 serotype IPD",
author = "{van Deursen}, {Anna M. M.} and {van Mens}, {Suzan P.} and Sanders, {Elisabeth A. M.} and Vlaminckx, {Bart J. M.} and {de Melker}, {Hester E.} and Schouls, {Leo M.} and {de Greeff}, {Sabine C.} and {van der Ende}, Arie",
year = "2012",
doi = "10.3201/eid1811.120329",
language = "English",
volume = "18",
pages = "1729--1737",
journal = "Emerging infectious diseases",
issn = "1080-6040",
publisher = "Centers for Disease Control and Prevention (CDC)",
number = "11",

}

RIS

TY - JOUR

T1 - Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands

AU - van Deursen, Anna M. M.

AU - van Mens, Suzan P.

AU - Sanders, Elisabeth A. M.

AU - Vlaminckx, Bart J. M.

AU - de Melker, Hester E.

AU - Schouls, Leo M.

AU - de Greeff, Sabine C.

AU - van der Ende, Arie

PY - 2012

Y1 - 2012

N2 - In the Netherlands, the national immunization program includes 7-valent pneumococcal conjugate vaccine (PCV7) for all newborns born after April 1, 2006. We compared the incidence of invasive pneumococcal disease (IPD) and patient and disease characteristics before PCV7 introduction (June 2004-June 2006) with those after PCV7 introduction (June 2008-June 2010). Culture-confirmed IPD cases were identified by 9 sentinel laboratories covering ≈25% of the Dutch population. Significant declines in overall IPD incidence were observed in children <2 (60%) and in persons >65 (13%) years of age. A trend toward gradual increases in non-PCV7 serotype IPD infections was observed in all age groups; the largest increases were among persons 50-64 (37%) and >65 (25%) years of age. In adults, the proportion of immunocompromised persons increased among IPD patients. Overall, deaths from IPD decreased from 16% to 12% because of a lower case-fatality rate for persons with non-PCV7 serotype IPD

AB - In the Netherlands, the national immunization program includes 7-valent pneumococcal conjugate vaccine (PCV7) for all newborns born after April 1, 2006. We compared the incidence of invasive pneumococcal disease (IPD) and patient and disease characteristics before PCV7 introduction (June 2004-June 2006) with those after PCV7 introduction (June 2008-June 2010). Culture-confirmed IPD cases were identified by 9 sentinel laboratories covering ≈25% of the Dutch population. Significant declines in overall IPD incidence were observed in children <2 (60%) and in persons >65 (13%) years of age. A trend toward gradual increases in non-PCV7 serotype IPD infections was observed in all age groups; the largest increases were among persons 50-64 (37%) and >65 (25%) years of age. In adults, the proportion of immunocompromised persons increased among IPD patients. Overall, deaths from IPD decreased from 16% to 12% because of a lower case-fatality rate for persons with non-PCV7 serotype IPD

U2 - 10.3201/eid1811.120329

DO - 10.3201/eid1811.120329

M3 - Article

C2 - 23092683

VL - 18

SP - 1729

EP - 1737

JO - Emerging infectious diseases

JF - Emerging infectious diseases

SN - 1080-6040

IS - 11

ER -

ID: 1781210